HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial.
Oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may address limitations of injectable and peptide-based agents for type 2 diabetes. To evaluate the efficacy and safety of HRS-7535, an oral nonpeptide GLP-1 RA, as add-on therapy among adults with type 2 diabetes inadequately…
Valorization of Cassia fistula pod waste into mesoporous carbon for the adsorptive removal of dye pollutant.
Valorization of agricultural waste into functional adsorbents provides a sustainable route for wastewater treatment. In this work, mesoporous activated carbon was synthesized from Cassia fistula pod waste through H₃PO₄ chemical activation and evaluated for methylene blue (MB) dye remov…
In the autoimmune disorder myasthenia gravis (MG), the nicotinic acetylcholine receptors (nAChRs) are the primary targets of pathogenic antibodies. While MG mechanisms have been extensively studied in animal models, functional insights into how antibody binding disrupts nAChR-dependent calcium signa…
Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap.
B cells drive B-cell malignancies and diverse autoimmune diseases through autoantibody production, antigen presentation, and cytokine dysregulation, and persistence of pathogenic B-cell or plasma-cell compartments. Across autoimmune diseases, the dominant pathogenic compartment varies, ranging from…
Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).
The ADAPT phase 3 trial (NCT03669588) showed efgartigimod was well tolerated and efficacious in acetylcholine receptor antibody-positive (AChR-Ab +) patients with generalized myasthenia gravis (gMG). This analysis utilized data from the ADAPT trial to investigate the efficacy and safety of ef…
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.
Certain psoriatic disease treatments, including tumor necrosis factor-α inhibitors (TNFi), increase tuberculosis (TB) risk. Testing for latent TB infection (LTBI) before initiating systemic therapy has been standard practice for psoriasis (PsO) patients; however, updated consensus states routi…
Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.
Aleniglipron is an oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) in development for obesity treatment. The ACCESS phase 2b placebo-controlled, double-blind study randomized 230 adults (mean BMI 39.5 kg m-2, 54% female) with obesity or overweight to examine the effect…
Burden of incident cardiovascular events in giant cell arteritis using data from a nationwide French cohort.
Giant cell arteritis (GCA) is one of the most common adult vasculitis. As large-scale studies on cardiovascular events in GCA are missing in France, our study examine their incidence using the French national medico-administrative health database. We included patients hospitalized for GCA between Ja…